Individualized Patient Assessment and Counseling for Transformed HBV Care: Research and Findings
True or False:
The primary purpose of anti-HBV therapy is to prevent progression to HBV-related liver complications, including decompensated cirrhosis, HCC, liver transplant, and death.
True. For more information on anti-HBV therapy, including strategies for selecting and initiating treatment, start the accredited CME activity on this page. (Han SH, Tran TT. Management of chronic hepatitis B: an overview of practice guidelines for primary care providers. J Am Board Fam Med. 2015;28(6):822-837.)
Joseph K. Lim, MD
Associate Professor of Medicine
Director, Yale Viral Hepatitis Program
New Haven, CT
Robert G. Gish, MD
Clinical Professor (Consultant) of Gastroenterology and Hepatology
Liver Transplant Program
Palo Alto, CA
University of Nevada School of Medicine
Adjunct Professor of Clinical Medicine
University of Nevada
Las Vegas, NV
Medical Director, Hepatitis B Foundation
Medical Director, Asian Pacific Health Foundation
San Diego, CA
Su Wang, MD, MPH
Center for Asian Health
Saint Barnabas Medical Center
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Kathryn Schaefer, MSN, RN
Lead Nurse Planner
East Lansing, MI
Monica Nicosia, PhD
Bryn Mawr, PA
Upon completion, participants should be able to:
- Identify patients who should be screened for HBV
- Interpret HBV test results
- Describe patient-specific strategies for managing HBV
This activity is intended for primary care physicians.
Series Overview/Statement of Need
Each year, hepatitis B virus (HBV) care in the United States (US) accounts for approximately $1 billion in healthcare spending and 3,000 patient deaths. The prevalence is estimated to be between 850,000 and 2.2 million people, with approximately 240,000 new cases. Asians and Hawaiian/Pacific Islanders are disproportionately affected, with reported prevalence rates exceeding 20%. Although a cure is not yet available, the early initiation of anti-HBV therapy has the potential to substantially improve patient outcomes and reduce the financial burden on the healthcare system. For this reason, the most recent HBV testing recommendations from the American Association for the Study of Liver Diseases (AASLD), Centers for Disease Control and Prevention (CDC), and United States Preventive Services Task Force (USPSTF) include recommendations for screening asymptomatic non-pregnant immigrants from regions that have an intermediate to high prevalence of HBV.
The identification of patients at risk of viral hepatitis and the subsequent initial testing fall into the purview of the primary care clinician. However, current HBV testing practices within at-risk populations, including foreign born Asians, often do not align with guideline recommendations.
This intervention is designed to provide timely and relevant education to support primary care teams’ pursuit of high-quality, coordinated HBV care.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses, nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CME activity consists of a 1.0-credit publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: December 22, 2017
Expiration Date: December 21, 2018
Estimated Time to Complete This Activity: 1 hour
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Robert G. Gish, MD
Consulting fees/advisory boards: Abbott Laboratories, AbbVie Inc., Access Biologicals, Alexion, Arrowhead Pharmaceuticals, Inc., AstraZeneca, Bayer Healthcare Pharmaceuticals, BioCollections Worldwide Inc., CoCrystal Pharma Inc., ContraVir Pharmaceuticals, Eiger BioPharmaceuticals, Enyo Pharma SA, Genentech, Gilead Sciences, Inc., Humabs BioMed, Intellia, Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., MedImmune, Merck & Co. Inc., Nanogen, Novira Therapeutics, Prometheus Laboratories Inc., Quest Diagnostics, Spring Bank Pharmaceuticals, Theranos Inc., Transgene, Vital Therapies, Inc.,
Fees received for promotional/non-CME activities: AbbVie Inc., Alexion, Bayer Healthcare Pharmaceuticals, Gilead Sciences, Inc., Merck & Co. Inc., Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC Contracted research: Gilead Sciences, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Alexion, Arrowhead Pharmaceuticals, Inc., Athenex, CoCrystal Pharma Inc., Riboscience LLC
Other (speakers bureau): AbbVie Inc., Alexion, Bayer Healthcare Pharmaceuticals, Gilead Sciences, Inc., Merck & Co. Inc., Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC
Joseph K. Lim, MD
Consulting fees/advisory boards: Bristol-Myers Squibb, Gilead Sciences, Inc.
Su Wang, MD, MPH, has indicated no real or apparent conflicts.
The peer reviewers, writer, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For CME-related questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: http://www.med-iq.com/privacy-statement/.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
© 2017 Med-IQ, LLC
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.